Giving contamination time to build up can cause headaches for more than just your company.
This article was also published in our US sister publication Pharmaceutical Technology and can be read here.
The company announced that an August 2016 FDA inspection of the company’s facility resulted in no form 483s.
This key bioprocessing segment is expecting continued growth.
Evonik’s parenteral drug delivery and commercial drug product manufacturing in Alabama passes EU GMP inspection.